Dr Ben L Pfeifer MD PhD  
Professor and Director for Clinical Research, Aeskulap Cancer Centre Switzerland

Specialities
Anesthesiology, Physiology, Cancer Immunology

1.Education and professional life in Germany from 1968-1984:

Medical Studies at Humboldt-University Berlin, Speciality Training (residency) at Humboldt-University Berlin, Assistant Professor and Senior Attending Physician Anesthesiology/Intensive Care at Humboldt- University Berlin; Associate Professor and Senior Attending Physician at Philipps University Marburg; Medical Director at Cancer and Pain Treatment Centre, Bad Mergentheim, Germany.

2. Education and professional life in U.S.A from 1985-1999:

Visiting Professor at University of South Florida (Cancer Immunology), Visiting Professor at University of California.

3. Education and professional life in Switzerland since 2000:

Director for Clinical Research at Aeskulap Cancer Centre, Brunnen, Switzerland.

Scientific Activities
55 publications in peer reviewed medical journals
1 book contribution
1 book published
56 presented papers at national and international medical conferences
Invited lecturer at the Academy of Sciences in Germany, Russia, USA and Poland

Honours
Humboldt-Prize
Immunological Research Prize, Florida, USA

Licenses
Medical Licenses for Germany, all European Countries, USA ( Florida)

Practice
Dr Pfeifer has more than 2,000 successful cases having treated hormon-refrectory prostate cancer patients using natural substances. Some of his experience on treatment of prostate cancer were presented in article: Phytotherapy for Prostate Cancer -Hope or Reality?

Further articles
Complementary medical therapies for hormone refractory prostate carcinoma

2006 - Phytonutrient-Therapy and Immune System Support for Patients with Hormone-Refractory Prostate Cancer
A non-toxic therapy protocol for patients with hormone-refractory prostate cancer will be presented. Treatment results of the clinical application of this protocol will be discussed using best case description as well as evidence based medicine criteria from a prospective clinical trial involving 194 patients.
Goals and objectives:

• Providing non-toxic and effective treatment for hormone-refractory prostate cancer.
• Prolonging life and improving quality of life for patients with hormone-refractory prostate cancer.